The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
=== Chemical synthesis === Digital Microfluidics (DMF) allows for precise manipulation and coordination in small-scale chemical synthesis reactions due to its ability to control micro scale volumes of liquid reagents, allowing for overall less reagent use and waste. This technology can be used in the synthesis compounds such as peptidomimetics and PET tracers. PET tracers require nanogram quantities and as such, DMF allows for automated and rapid synthesis of tracers with 90-95% efficiency compared to conventional macro-scale techniques. Organic reagents are not commonly used in DMF because they tend to wet the DMF device and cause flooding; however synthesis of organic reagents can be achieved through DMF techniques by carrying the organic reagents through an ionic liquid droplet, thus preventing the organic reagent from flooding the DMF device. Droplets are combined together by inducing opposite charges thus attracting them to each other. This allows for automated mixing of droplets. Mixing of droplets are also used to deposit MOF crystals for printing by delivering reagents into wells and evaporating the solutions for crystal deposition. This method of MOF crystal deposition is relatively cheap and does not require extensive robotic equipment. Chemical synthesis using digital microfluidics (DMF) has been applied to many noteworthy biological reactions. These include polymerase chain reaction (PCR), as well as the formation of DNA and peptides.
==== United States ==== 4-HO-DPT is not an explicitly controlled substance in the United States. However, the drug is a close analogue of psilocin (4-HO-DMT), which is a Schedule I controlled substance in this country, and hence sale for intended human consumption could be illegal under the Federal Analogue Act.
Two adults and five children at the Kindercare kindergarten in Christchurch suffer chemical burns after being accidentally exposed to a hazardous substance being poured on a waterslide. The Controller and Auditor-General of New Zealand launches an investigation into the Chatham Islands Council's expenditure and procurement policies. Craig Stobo temporarily steps down as chairperson of the Financial Market Authority pending an investigation by the Ministry of Business, Innovation and Employment (MBIE). 6 December — A measles case is reported in Queenstown, bringing the total number of cases reported nationally to 30. 22 cases are no longer infectious. 8 December: A wildfire engulfs over 320 hectares of Tongariro National Park, leading to the closure of sections of State Highway 47. Significant firefighting resources including 60 firefighters, 16 vehicles and nine helicopters are deployed to contain the blaze. The National Iwi Chairs Forum delivers a 24,000-strong petition urging the Education Minister Erica Stanford to reverse an amendment abolishing the requirement for school boards to uphold the Treaty of Waitangi. 9 December: The Supreme Court of New Zealand rules that two parents who care for their severely disabled adult children should be recognised as homeworkers who are entitled to the minimum wage. The New Zealand Government announces two proposed bills to replace the Resource Management Act 1991.
They were, collectively, a very representative group: two engineers, two chemists, two biologists, one representative of agricultural science, one geologist, one representative of veterinary science, one representative of manufacturing industries, and one representative of the agricultural and pastoral industries. Robertson attended the Council's first official meeting, in Melbourne, on 22 June 1926, as the acting chairman of the South Australian Committee.
=== Leader of the BC Conservatives (May–September 2026) === On May 30, 2026, Findlay was elected leader of the Conservative Party of British Columbia with 51% of the vote. She took over from interim leader Trevor Halford following the resignation of John Rustad in December 2025. During the leadership campaign, Findlay faced criticism within her own party for saying fellow leadership candidate Peter Milobar had a conflict of interest when it comes to reconciliation because his wife is Indigenous. In response, Milobar called Findlay's attacks "the worst side of politics possible,” suggesting her victory would “give a lot of British Columbians pause for thought of whether they would actually vote for a party like this.” He would later leave the party in August 2026. Findlay has also received criticism from former Conservative MLA Elenore Sturko, who called her "radical on the right wing," saying she’s been copied on several emails from B.C. Conservative members cancelling their memberships. Former BC United MLA Karin Kirkpatrick called Findlay's victory "very, very bad for the Conservative party." On June 29, she conducted a shadow cabinet reshuffle, appointing MLA Heather Maahs as leader of the Opposition. On July 3, 2026, former BC Conservative MLA Amelia Boultbee crossed the floor to join the governing BC NDP caucus, citing a shift toward "Trump-style populism" under new BC Conservative leader Findlay as the reason she would not be returning to its caucus.
Sources: en.wikipedia.org
=== Compression gloves === Compression gloves are handwear designed to help prevent the occurrence of various medical disorders relating to blood circulation in the wrists and hands. They can be used to treat the symptoms of arthritis, though the medical benefits may be limited.
Tavapadon, sold under the brand name Juvmo, is a dopamine receptor agonist used for the treatment of Parkinson's disease. It is taken by mouth. Tavapadon was approved for medical use in the United States in September 2026.
== Effects == Baikiain is hypothesized to be the causative agent of illnesses resulting from consumption of food products containing tara flour. In several cases documented in 2022 people became ill after consuming meals containing tara flour with high concentrations of Baikian (3% dry weight). People experienced acute gastrointestinal and liver disease with clinical signs of hepatotoxicity. Baikiain was found not to harm mammalian or human cells in culture but did cause liver injury and depletion of glutathione in rodent models.
== Endolithic fungi and algae in marine ecosystems == Although it is possible that endolithic fungi could play an important role in the health of coral reefs, only limited research has been conducted on the distribution and diversity of marine endolithic fungi. Endolithic fungi have been discovered in shells as early as the year 1889 by Edouard Bornet and Charles Flahault. These two French phycologists specifically provided descriptions for two fungi: Ostracoblabe implexis and Lithopythium gangliiforme. Discovery of endolithic fungi, such as Dodgella priscus and Conchyliastrum, has also been made in the beach sand of Australia by George Zembrowski. Findings have also been made in coral reefs and have been found to be, at times, beneficial to their coral hosts. In the wake of worldwide coral bleaching, studies have suggested that the endolithic algae located in the skeleton of the coral may be aiding the survival of coral species by providing an alternative source of energy. Although the role that endolithic fungi play is important in coral reefs, it is often overlooked because much research is focused on the effects of coral bleaching as well as the relationships between Coelenterate and endosymbiotic Symbiodinia. According to a study done by Astrid Gunther endoliths were also found in the island of Cozumel (Mexico). The endoliths found there not only included algae and fungi but also included cyanobacteria, sponges as well as many other microborers.
endonuclease Any enzyme whose activity is to cleave phosphodiester bonds within a chain of nucleotides, including those that cleave relatively nonspecifically (without regard to sequence) and those that cleave only at very specific sequences (so-called restriction endonucleases). When recognition of a specific sequence is required, endonucleases make their cuts in the middle of the sequence. Contrast exonuclease.
Sources: en.wikipedia.org
Normally, cytokine production in and around the wounded area increases to fight infection and control healing (and, possibly, to control pain), but pre-incisional morphine administration (0.1 mg/kg to 10.0 mg/kg) reduced the number of cytokines found around the wound in a dose-dependent manner. The authors suggest that morphine administration in the acute post-injury period may reduce resistance to infection and may impair the healing of the wound.
=== United Kingdom === The following programs of study have currently been approved by the General Dental Council for the profession of clinical dental technologist. Required prerequisites must be completed prior to enter Clinical Dental Technology Program. On successful completion of the selected courses, individuals are required to register with the General Dental Council to practice legally as a clinical dental technologist.
=== No development reported === Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor negative allosteric modulator EX-597 (KDS-4103; ORG-231295; URB-597) – fatty acid amide hydrolase (FAAH) inhibitor Guanfacine extended-release (Connexyn; Intuniv; Intuniv XR; S-877503; SHP-503; SPD-503) – α2-adrenergic receptor agonist
Initial clinical trial results with IgG4 PD1 antibody nivolumab were published in 2010. It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy. Pembrolizumab (Keytruda) is another PD1 inhibitor that was approved by the FDA in 2014. Pembrolizumab is approved to treat melanoma and lung cancer. Antibody BGB-A317 is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.
=== Primary Sources === Banks, Iain M. (1987), Consider Phlebas, Orbit, ISBN 1-85723-138-4. Banks, Iain M. (1988), The Player of Games, Orbit, ISBN 1-85723-146-5. Banks, Iain M. (1990), Use of Weapons, Orbit, ISBN 9780356191607. Banks, Iain M. (1991). The State of the Art. Orbit. ISBN 0-356-19669-0.. Banks, Iain M. (10 August 1994). "A Few Notes on the Culture". Newsgroup: rec.arts.sf.written. Retrieved 3 August 2021.. Banks, Iain M. (1996), Excession, Orbit, ISBN 1-85723-457-X. Banks, Iain M. (1998), Inversions, Orbit, ISBN 1-85723-763-3. Banks, Iain M. (2000), Look to Windward, Orbit, ISBN 1-85723-969-5. Banks, Iain M. (2008), Matter, Orbit, ISBN 978-1-84149-417-3. Banks, Iain M. (2010), Surface Detail, Orbit, p. 400, ISBN 978-1-84149-893-5. Banks, Iain M. (2012), The Hydrogen Sonata, Orbit, ISBN 978-0356501505. Banks, Iain M. (n.d.), "A few Notes on Marain", Trevor Hopkins Homepage, retrieved 9 August 2021.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.